首页> 外文期刊>Frontiers in Oncology >Prognostic Significance of Systematic Lymphadenectomy in Patients With Optimally Debulked Advanced Ovarian Cancer: A Meta-Analysis
【24h】

Prognostic Significance of Systematic Lymphadenectomy in Patients With Optimally Debulked Advanced Ovarian Cancer: A Meta-Analysis

机译:最佳消亡的晚期卵巢癌患者系统淋巴结切除术的预后意义:META分析

获取原文
       

摘要

Background: The effect of systematic lymphadenectomy (SL) on survival in patients with optimally debulked advanced ovarian cancer remains unclear. We evaluated the therapeutic value of SL in advanced ovarian cancer patients who underwent primary optimal debulking surgery. Methods: A meta-analysis was carried out using articles retrieved from the PubMed, Embase, and Cochrane databases. Overall survival (OS) and progression-free survival (PFS) were compared between patients who underwent SL and those who underwent unsystematic lymphadenectomy (USL). Results: Seven studies that included 2,425 patients with advanced ovarian cancer were included in the meta-analysis. The overall analyses indicated significantly improved OS [hazard ratio (HR) = 0.64, 95% confidence interval (CI): 0.49–0.84, P & 0.01] but not PFS (HR = 0.89, 95% CI: 0.69–1.15, P = 0.38) in patients who underwent SL compared to those who underwent USL. Subgroup analyses based on study type, study quality, total numbers of patients, and International Federation of Gynecology and Obstetrics (FIGO) stage provided similar results. However, subgroup analysis of patients with no residual tumor revealed that SL was not associated with improved OS (HR = 0.81, 95% CI: 0.66–1.00, P = 0.05) or PFS (HR = 1.09, 95% CI: 0.91–1.30, P = 0.33). Conclusions: In patients with optimally debulked advanced ovarian cancer, SL may improve OS but not PFS. However, SL does not provide a survival advantage when macroscopically complete resection of all visible tumors is achieved.
机译:背景:系统淋巴结切除术(SL)对最佳消亡的晚期卵巢癌患者存活的影响尚不清楚。我们评估了在接受初级最佳消泡手术的晚期卵巢癌患者中SL的治疗价值。方法:使用从PubMed,Embase和Cochrane数据库中检索的物品进行META分析。在接受SL和未经系统淋巴结切除术(USL)的患者之间比较总存活(OS)和无进展的存活(PFS)。结果:七项研究包括2,425名晚期卵巢癌患者的荟萃分析。整体分析表明OS [危险比(HR)= 0.64,95%置信区间(CI):0.49-0.84,P& 0.01]但没有PFS(HR = 0.89,95%CI:0.69-1.15,p = 0.38),与接受USL的人进行接受的患者。基于研究类型,学习质量,患者总数,以及国际妇科和妇产业联合会(FICO)阶段的亚组分析提供了类似的结果。然而,没有残留肿瘤患者的亚组分析显示,SL与改进的OS无关(HR = 0.81,95%CI:0.66-1.00,P = 0.05)或PFS(HR = 1.09,95%CI:0.91-1.30 ,p = 0.33)。结论:在最佳消亡的晚期卵巢癌患者中,SL可能会改善OS但不是PFS。然而,当宏观完全切除所有可见肿瘤的切除时,SL不提供存活的优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号